ALSO NOTED: Dyloject hits primary endpoint; StaphVax boosts antibodies; Aphton touts cancer trial; and much more...

> Intrac announced that a pivotal trial of Dyloject met its primary endpoint on pain relief. Release

> Nabi Biopharmaceuticals says that a mid-stage trial of its StaphVax vaccine showed that it helped boost antibodies in 90 percent of heart surgery patients. Story

> Shares of Aphton surged this morning after the biotech reported that a small Phase I trial of its experimental cancer treatment IGN311 demonstrated anti-tumor activity. Article

> Former McKesson CFO Richard Hawkins was found not guilty of fraud. Story

> Doctors have found that Lorenzo's Oil does indeed prevent a rare genetic disease. Story

And Finally... The Boston Globe looks at how doctors swiftly began to use Natrecor in outpatient clinics in a variety of ways that had never been tested for safety. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.